Software quality assurance engineers know there’s no such thing as “defect free” software. It’s all about making a judgment call as to when none of the outstanding defects qualify as showstoppers. Even the miraculous system that makes up the human body makes mistakes. “A genetic disorder is a disease caused in whole or in part by a change in the DNA sequence away from the normal sequence,” says the NHGRI. Some 5,000 diseases are caused by mutating DNA which could be corrected by editing the genes that are causing the problem. That’s the gene-editing investment thesis in a nutshell, and it’s why investors have been poring over the list of 27 gene-editing stocks out there trying to select the winner(s). Today, we’re going to look at the 28th gene-editing stock to come across our radar – Prime Medicine (PRME) – which recently announced plans to have an initial public offering (IPO).
We believe Prime Editing technology has the potential to provide life-long cures after a single treatment.
Credit: Prime Medicine
About Prime Medicine Stock
In our recent piece on Beam Therapeutics (